Stockscreener 앱 받기
24.93
4.79%
1.14
시간 외 거래:
24.93
전일 마감가:
$23.79
열려 있는:
$23.97
하루 거래량:
229.65K
Relative Volume:
0.66
시가총액:
$1.38B
수익:
$29.71M
순이익/손실:
$-69.15M
주가수익비율:
-22.16
EPS:
-1.1251
순현금흐름:
$-52.28M
1주 성능:
+3.32%
1개월 성능:
-0.97%
6개월 성능:
+40.37%
1년 성능:
+66,916%
1일 변동 폭
$23.45
$25.10
1주일 범위
$23.45
$25.30
52주 변동 폭
$14.72
$34.19
Aktis Oncology Inc Stock (AKTS) Company Profile
명칭
Aktis Oncology Inc
전화
978-237-4380
주소
17 DRYDOCK AVENUE, BOSTON, NC
Compare AKTS vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AKTS
Aktis Oncology Inc
|
24.93 | 1.33B | 29.71M | -69.15M | -52.28M | -1.1251 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Aktis Oncology Inc Stock (AKTS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-09 | 개시 | H.C. Wainwright | Buy |
| 2026-02-03 | 개시 | BofA Securities | Buy |
| 2026-02-03 | 개시 | JP Morgan | Overweight |
| 2026-02-03 | 개시 | Leerink Partners | Outperform |
| 2026-02-03 | 개시 | TD Cowen | Buy |
| 2024-01-04 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-09-06 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2023-01-24 | 개시 | B. Riley Securities | Buy |
| 2021-02-02 | 재확인 | Craig Hallum | Buy |
| 2021-01-15 | 재확인 | Craig Hallum | Buy |
| 2019-09-18 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2019-07-10 | 업그레이드 | Northland Capital | Market Perform → Outperform |
| 2019-05-13 | 재확인 | Craig Hallum | Buy |
| 2019-02-05 | 재확인 | Craig Hallum | Buy |
| 2019-02-05 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2018-12-18 | 개시 | Craig Hallum | Buy |
| 2018-11-30 | 개시 | Lake Street | Buy |
| 2018-06-22 | 개시 | Loop Capital | Buy |
| 2018-02-09 | 개시 | Drexel Hamilton | Buy |
모두보기
Aktis Oncology Inc 주식(AKTS)의 최신 뉴스
Aktis Oncology, Inc.: Target Price Consensus and Analysts Recommendations | AKTS | US01021M1045 - marketscreener.com
AKTS SWOT Analysis: Financial Resilience Amidst Clinical Development Challenges Revealed in 10-Q Filing - GuruFocus
Aktis Oncology (NASDAQ:AKTS) Posts Earnings Results, Meets Expectations - marketbeat.com
Aktis Oncology Q2 EPS misses estimate, sales beat consensus - scanx.trade
Aktis: Q2 Earnings Snapshot - KVUE
Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026 - The Manila Times
Aktis Oncology (AKTS) builds cash to $517M as losses rise with clinical spend - Stock Titan
Aktis Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Aktis Oncology (AKTS) posts Q2 2026 results with $517M cash runway into 2029 - Stock Titan
Aktis Oncology (NASDAQ:AKTS) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Aktis Oncology (AKTS) Expected to Release Earnings on Monday - MarketBeat
Insider Selling: Aktis Oncology (NASDAQ:AKTS) Director Sells 4,856 Shares of Stock - marketbeat.com
AKTS|Akoustis Technologies Ord Shs|Price:24.170|Chg%:+0.280 - TradingKey
Has Aktis Oncology (AKTS) Fallen Far Enough To Be Below Fair Value? - simplywall.st
AKTIS ONCOLOGY INC : LEERINK PARTNERS ASSUMES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $33 - Bitget
Aktis Oncology Inc : Leerink Partners Assumes - Moomoo
Aktis Oncology director Ken Herrmann sells $119,274 in stock By Investing.com - Investing.com Australia
Aktis Oncology (NASDAQ:AKTS) Stock Passes Above 50 Day Moving AverageHere's Why - marketbeat.com
Form 4 Aktis Oncology Inc For: 21 July By Investing.com - Investing.com Nigeria
Aktis Oncology (AKTS) director sells 4,856 shares after exercising options - Stock Titan
Aktis Oncology director Ken Herrmann sells $119,274 in stock - Investing.com
Aktis Oncology director Ken Herrmann disposes of common shares worth $119,256.78 - Bitget
Aktis Oncology director Ken Herrmann disposes of 3,065 common shares worth $77,279.54 - Bitget
AKTS Pulls Back After Recent Gains: Key Levels to Watch for Aktis Oncology (AKTS)Volatility Skew - dars.gov.et
Aktis Oncology, Inc. (AKTS) director sells 3,065 post-exercise - Stock Titan
Akoustis Technologies (AKTS) insider plans 4,856-share stock sale after option exercise - Stock Titan
AKTS Options Chain — NASDAQ:AKTS - TradingView
Enterprise value to EBIT forward of Aktis Oncology, Inc. – NASDAQ:AKTS - TradingView
Enterprise value to revenue forward of Aktis Oncology, Inc. – NASDAQ:AKTS - TradingView
Form 144 AKTIS ONCOLOGY For: 17 July By Investing.com - Investing.com Nigeria
Aktis Oncology, Inc. SEC Filing (Jul 17, 2026) - Stock Titan
AKTS Options Volatility — NASDAQ:AKTS - TradingView
Price to sales forward of Aktis Oncology, Inc. – NASDAQ:AKTS - TradingView
New Options Listings Include Aktis Oncology Inc (AKTS) - GuruFocus
J.P. Morgan Keeps Their Buy Rating on Aktis Oncology, Inc. (AKTS) - The Globe and Mail
AKTS Maintained by JP Morgan -- Price Target Raised to $33.00 - GuruFocus
J.P. Morgan Maintains Aktis Oncology(AKTS.US) With Buy Rating, Raises Target Price to $33 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Price to book forward of Aktis Oncology, Inc. – NASDAQ:AKTS - TradingView
Price to earnings forward of Aktis Oncology, Inc. – NASDAQ:AKTS - TradingView
Enterprise value to EBITDA forward of Aktis Oncology, Inc. – NASDAQ:AKTS - TradingView
Aktis oncology CMO sells $1.39m in shares By Investing.com - Investing.com India
Aktis Oncology COO Ron-Bigger sells $1.39m in shares - Investing.com UK
Aktis Oncology Insider Sold Shares Worth $1,387,558, According to a Recent SEC Filing - Moomoo
Aktis Oncology COO Ron-Bigger sells $1.39m in shares By Investing.com - Investing.com Australia
Aktis oncology CMO sells $1.39m in shares - Investing.com
Form 4 Aktis Oncology Inc For: 10 July By Investing.com - Investing.com South Africa
Aktis Oncology Insider Sold Shares Worth $1,388,701, According to a Recent SEC Filing - Moomoo
Aktis Oncology Insiders Sold Shares Worth Over $2.8M - TradingView
Aktis Oncology (AKTS) COO exercises 50,000 options and sells matching shares - Stock Titan
Aktis Oncology (AKTS) CMO exercises 50,000 options, sells 50,000 shares in July 8 trades - Stock Titan
Aktis Oncology Inc (AKTS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.07%
자본화:
|
볼륨(24시간):